Abstract
1370P -The results of treatment of non-small cell lung cancer stage III with a preoperative vinorelbine/carboplatin and personalized adjuvant chemotherapy

Background
Individual chemotherapy based on the determination of molecular biomarkers of chemosensitivity is a new way to treat patients with NSCLC. Promising markers for chemosensitivity are monoresistance genes such as BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBB3, TYMS, and ABCC5.
Methods
We enrolled and analyzed 62 patients with stage III NSCLC. All the patients have received 2 courses of neoadjuvant chemotherapy vinorelbine/carboplatin and surgery. Then patients were randomly assigned (1:1 ratio) to either the personalized adjuvant chemotherapy arm (main group) or the adjuvant chemotherapy vinorelbine/carboplatin arm (control group). In the main group, carboplatincontaining doublets were assigned based on monoresistance gene expression levels ABCC5, RRM1, ERCC1, BRCA1, TOP1, TOP2α, TUBB3 and TYMS. RNA was extracted from tumor after neoadjuvant chemotherapy using "RNeasy Plus Mini Kit" (QIAGEN, Germany). The analysis of monoresistance genes expression was done by qRT-PCR method. A χ 2 test was used to analyze gene expression in relation to clinicopathological parameters. The survival rates were calculated by the Kaplan-Meier method.
Results
The follow-up period was 4 -76 months. In the main group, the disease progression was observed in 6 patients (19.4%), in the control group -15 patients (48.4%). Three-year disease-free survival in the main group was 80.7% (median DFS not achieved), in the control group -51.6%, median DFS -34 months (HR: 2.56, 95% CI: 1.09 -6,03); differences are statistically significant: Log-Rank test χ2=4.196, p = 0.041. There was no difference in three-year overall survival (main group: 87.1%, control group: 67.7%, HR: 2.27, 95% CI: 0.79 -6,47).
Conclusions
Personalized postoperative chemotherapy based on the determination of monoresistance gene expression after neoadjuvant chemotherapy allows significant increase of patients 3-year diseasefree survival by 29.1%.
Legal entity responsible for the study
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
Funding:
Has not received any funding.
Disclosure: All authors have declared no conflicts of interest. 
1431P -TP53 mutations impair overall survival of TKI-treated patients with oncogenedriven NSCLC
Background
Tyrosine kinase inhibitors (TKI) have considerably improved survival of patients with oncogene-driven non-small cell lung cancer (NSCLC). However, prognosis varies widely, and identification of molecular factors with a critical role for adverse outcome could facilitate further advances in management.
Methods
We retrospectively studied the clinical course of patients with metastatic epidermal growth factor receptor (EGFR)-or anaplastic lymphoma kinase (ALK)-driven NSCLC and known baseline TP53 status that received TKI at our institutions. Overall survival (OS) from the start of treatment for metastatic disease was analyzed according to Kaplan-Meier or by Cox regression.
Results
A total of n = 149 EGFR + and n = 76 ALK + patients were included with a median age of 62 years (interquartile range [IQR] 19), a median ECOG performance status of 0.5 (IQR 1) and a predominance of female (136/225=60%) never-/light-smokers (median number of pack-years 9, IQR 16). Median OS was 36 months for EGFR + and 44 months for ALK + NSCLC patients. TP53 mutations were present at diagnosis in 34% (51/149) of EGFR + and 19% (15/76) of ALK + patients, and they were associated with inferior OS in both EGFR + (24 vs. 40 months in median, p = 0.027) and ALK + NSCLC (24 vs. 53 months, p = 0.001). Their adverse effect was comparable to that of a worse initial clinical condition as reflected by an ECOG performance status of 1 compared to 0 (HR = 1.8 for ECOG vs. 1.8 for TP53 mutations in EGFR + patients, and HR = 4.1 for ECOG vs. 3.7 for TP53 mutations in ALK + patients, all p < 0.05 in bivariable analyses), and it was independent from that of the oncogene variant in both patient groups (HR = 1.9 for other EGFR alterations vs. exon 19 indels, and HR = 1.8 for TP53 mutations vs. wild-type in EGFR + patients; HR = 2.3 for EML4-ALK V3 vs. V1/V2, and HR = 4.7 for TP53 mutations vs. wild-type in ALK + patients, all p < 0.05 in bivariable analyses).
Conclusions
TP53 mutations impair overall survival of TKI-treated patients with EGFR-and ALK-driven NCSLC independent of baseline clinical status and oncogene variant. Their detection could assist selection of cases for more aggressive management. Preclinical exploration of their role in acquired TKI resistance could guide novel therapeutic strategies. gen. to 3 rd gen. TKI (30%) appeared to be low and it is questionable whether these data represent real world sequencing treatment patterns. Therefore, we investigated the sequence pattern, i.e. the percentage of 2 nd line therapy in EGFR mt+ pts in 3 certified lung cancer centers in Germany.
1447P -Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts
Methods
Data of 912 of 1477 pts tested for EGFR mutations were analyzed between 2009-2017. 140/144 pts with an activating EGFR mt + (16%) and treated with systemic therapy (4 pts received no therapy) were identified and their treatments were captured as well as their outcome. 36 pts were treated before accessibility to 3 rd generation TKI and 104 pts after accessibility to 3 rd generation TKI. nd line therapy were pts refusal (n = 2), bad PS (n = 26) frequently due to CNS metastases, fast progression and death (n = 6). After accessibility of 3 rd gen. TKI, 20 of 66 (30%) pts did not receive 2 nd line therapy. Median OS of the overall cohort was 27 months (n = 140), median OS of pts receiving 2 nd line (n = 78) vs. no 2 nd line (n = 62) was 36 vs. 14 months (p < 0.0001). After accessibility of 3 rd gen. TKI 30/104 pts (29%) receive a 3 rd gen. TKI after 1 st line or 2 nd line therapy. Median OS of pts receiving (n = 30) and not receiving 3rd gen. TKI (n = 110) was 55 months vs. 22 months (p < 0.0001).
Results
130
Conclusions
In real world, a significant number of pts treated with 1 st or 2 nd gen. TKI do not reach 2 nd line therapy even when 3 rd gen. TKI were accessible. Reasons for not receiving 2 nd line therapy are in most cases deterioration of PS and lack of possibility to test for T790M in the minority of cases (n = 28/66, 42% were not tested). These data, although favorable for the small and very selected cohort of pts treated with Osimertinib, might argue for the most effective therapy in 1 st line for pts with EGFR mt+ tumors.
